ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia

Jianbiao Zhou, Jessie Yiyi Quah, Yvonne Ng, Jing-Yuan Chooi, Sabrina Hui-Min Toh, Baohong Lin, Tuan Zea Tan, Hiroki Hosoi, Motomi Osato, Qihui Seet, A.G. Lisa Ooi, Bertil Lindmark, Mark McHale, and Wee-Joo Chng

Disclosures: Q.S., A.G.L.O., B.L., M.M., were employees of ASLAN Pharmaceuticals. C.W.J. received research fund from ASLAN Pharmaceuticals. All other authors declare no competing interests.

Contributions: W.J.C. designed experiments, supervised the project, and wrote the manuscript. J.Z. designed and conducted the experiments, analysed data and wrote the manuscript. J.Y.Q., Y.N., J.Y.C., S.H.T., B.L. performed the experiments. T.Z.T. conducted RNA-seq data analysis. H.H. contributed to the PDX experiments. M.O. provided expertise in mouse experiments, discussions and revised the manuscript. Q.S., A.G.L.O., B.L., M.M. provided critical reagents, expert opinion and revised the manuscript.